Abstract
Previous research studies confirm that molecules containing 1,2,3-triazole moiety are potential anticancer agents which elevates effectiveness and reduces drug resistance. Present study was aimed to evaluate the anticancer activity of the synthesized novel title compound 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine (BTCP). The structural and spectral characteristics of BTCP were studied and compared with DFT results. NBO, HOMO and LUMO energies, Mulliken atomic charges and molecular electrostatic potential surface were investigated. The bioavailability of BTCP was confirmed by pharmacological investigations using Molinspiration and PreADMET online servers. Molecular docking studies verified the inhibitory nature of BTCP against human topoisomerase IIα enzyme (1ZXM) over standard drug doxorubicin. MTT assay technique has been employed to study anticancer activity of BTCP with three human cancer cell lines (A549, MDAMB-231, PC-3) along with existing drug doxorubicin. The results of docking and anticancer activity specify that BTCP could be regarded as an alternative anticancer drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
